SecSonar.com

Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Intellia Therapeutics, Inc. (NTLA) is a Biotechnology company based in US with a market capitalization of $1.6B. Revenue grew 16.9% year-over-year and free cash flow was negative at -$354.7M. This page tracks NTLA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 403 employees · IPO May 6, 2016

Valuation

Valuation & price

$13.67 · as of May 17, 2026 · -51.1% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.36

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$26.97$17.50$8.04Jul 25Dec 25Jul 26Jul 7, 25$10.25Jul 9, 25$12.13Jul 11, 25$11.54Jul 15, 25$11.48Jul 17, 25$11.83Jul 21, 25$12.63Jul 23, 25$14.24Jul 25, 25$13.60Jul 29, 25$12.50Jul 31, 25$11.64Aug 4, 25$12.12Aug 6, 25$11.37Aug 11, 25$10.74Aug 13, 25$11.00Aug 15, 25$10.99Aug 19, 25$10.29Aug 21, 25$10.13Aug 25, 25$11.38Aug 27, 25$11.42Aug 29, 25$11.36Sep 3, 25$11.71Sep 5, 25$12.06Sep 9, 25$11.88Sep 11, 25$11.42Sep 16, 25$12.27Sep 18, 25$16.11Sep 22, 25$17.26Sep 24, 25$17.76Sep 26, 25$16.31Sep 30, 25$17.27Oct 2, 25$20.44Oct 6, 25$20.54Oct 8, 25$24.47Oct 10, 25$24.52Oct 14, 25$23.90Oct 16, 25$24.91Oct 21, 25$26.97Oct 23, 25$25.89Oct 27, 25$14.79Oct 29, 25$13.12Oct 31, 25$12.62Nov 4, 25$12.20Nov 6, 25$12.32Nov 10, 25$9.73Nov 12, 25$9.49Nov 14, 25$8.70Nov 18, 25$8.47Nov 20, 25$8.04Nov 25, 25$8.55Nov 28, 25$8.99Dec 2, 25$8.10Dec 4, 25$9.74Dec 8, 25$9.44Dec 10, 25$9.37Dec 12, 25$9.02Dec 16, 25$9.12Dec 18, 25$8.88Dec 22, 25$9.70Dec 24, 25$9.59Dec 29, 25$9.14Jan 2, 26$9.21Jan 6, 26$9.73Jan 8, 26$10.52Jan 12, 26$11.43Jan 14, 26$12.02Jan 16, 26$12.50Jan 21, 26$14.03Jan 23, 26$14.63Jan 27, 26$14.83Jan 29, 26$13.90Feb 2, 26$13.06Feb 4, 26$12.36Feb 9, 26$12.49Feb 11, 26$12.00Feb 13, 26$11.87Feb 18, 26$12.48Feb 20, 26$12.64Feb 24, 26$13.58Feb 26, 26$14.28Mar 2, 26$15.44Mar 4, 26$13.82Mar 6, 26$13.44Mar 10, 26$13.47Mar 12, 26$12.85Mar 17, 26$13.48Mar 19, 26$13.15Mar 23, 26$13.11Mar 25, 26$13.26Mar 27, 26$12.37Mar 31, 26$12.82Apr 2, 26$13.13Apr 7, 26$13.55Apr 9, 26$13.83Apr 13, 26$14.26Apr 15, 26$14.94Apr 17, 26$14.95Apr 22, 26$16.57Apr 24, 26$13.63Apr 28, 26$13.20Apr 30, 26$13.48May 4, 26$13.87May 6, 26$13.85May 8, 26$14.09May 12, 26$13.99May 14, 26$13.09May 18, 26$12.69May 20, 26$12.26May 22, 26$12.60May 28, 26$13.68Jun 1, 26$13.73Jun 3, 26$13.02Jun 5, 26$13.54Jun 9, 26$12.89Jun 11, 26$12.35Jun 15, 26$14.92Jun 17, 26$15.20Jun 22, 26$15.75Jun 24, 26$15.50Jun 26, 26$16.68Jul 2, 26$17.56
$8.0452-week range$27.98
Loading valuation history…

Fundamentals

Key fundamentals

$1.6B

Market cap

16.9%

Revenue growth (YoY)

76.5%

Gross margin

-$354.7M

Free cash flow (USD)

-$356.6M

Net debt

Net cash position

9.6%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$16.5MFY 2017$26.1MFY 2018$30.4MFY 2019$43.1MFY 2020$58.0MFY 2021$33.1MFY 2022$52.1MFY 2023$36.3MFY 2024$57.9MFY 2025$67.7M
$16.5M$67.7M

Free cash flow by year

2016 → 2025

FY 2016$29.9MFY 2017$-75.4MFY 2018$-67.6MFY 2019$-110.0MFY 2020$-53.5MFY 2021$-237.8MFY 2022$-391.7MFY 2023$-408.1MFY 2024$-354.7MFY 2025$-354.7M
$29.9M-$354.7M

Gross margin by year

2021 → 2025

FY 202179.2%FY 202285.5%FY 202375.3%FY 202482.2%FY 202576.5%
79.2%76.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 11, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventPhase 3 Results AnnouncementJun 15, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 10, 2026Filing
  • 8-K eventEarnings ReleaseMay 11, 2026Filing
  • Quarterly report10-Q FiledMay 11, 2026Filing
  • 8-K eventStock Offering AgreementApr 30, 2026Filing
  • 8-K eventPhase 3 Trial DataApr 27, 2026Filing
  • 8-K eventBy-Laws AmendedApr 10, 2026Filing

Questions

Frequently asked questions

What is Intellia Therapeutics, Inc.'s market cap?

Intellia Therapeutics, Inc. (NTLA) has a market capitalization of $1.6B.

What is NTLA's P/E ratio?

A meaningful P/E ratio is not available for NTLA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is NTLA's price-to-book (P/B) ratio?

NTLA trades at 2.36 times book value per share.

Are insiders buying NTLA stock?

SEC Form 4 filings show no open-market insider buys at Intellia Therapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

VRDN

Viridian Therapeutics, Inc.

$1.6B

INVA

Innoviva, Inc.

$1.6B

RXRX

Recursion Pharmaceuticals, Inc.

$1.6B

VIR

Vir Biotechnology, Inc.

$1.6B

NRIX

Nurix Therapeutics, Inc.

$1.5B

IMTX

Immatics N.V.

$1.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.